Gossamer Bio Inc GOSS.OQ GOSS.O is expected to show a rise in quarterly revenue when it reports results on May 15 for the period ending March 31 2025
The San Diego California-based company is expected to report revenue of $4.067 million, according to the mean estimate from 7 analysts, based on LSEG data.
‚ÄčLSEG's mean analyst estimate for Gossamer Bio Inc is for a loss of 19 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč
Wall Street's median 12-month price target for Gossamer Bio Inc is $7.00‚Äč, above‚Äč its last closing price of $1.10. ‚Äč‚Äč‚Äč
Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč
QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.17
-0.15
Beat
11.8
Sep. 30 2024
-0.12
-0.15
-0.14
Beat
5.3
Jun. 30 2024
0.31
0.23
0.22
Missed
-3.9‚Äč
Mar. 31 2024
-0.19
-0.19
-0.19
Met
-0.5
‚Äč‚ÄčDec. 31 2023
-0.19
-0.21
-0.21
Met
-1
Sep. 30 2023
-0.24
-0.26
-0.21
Beat
17.8‚Äč
Jun. 30 2023
-0.48
-0.49
-0.45
Beat
8
Mar. 31 2023
-0.52
-0.53
-0.52
Beat
1.8
This summary was machine generated May 13 at 11:13 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)